An antimicrobial agent trimethoprim-sulfamethoxazole (Tmp-Smx)does not usually cause electrolyte disturbances at regular doses, and few cases ofTmp-Smx-inducedelectrolyte imbalance have been reported in the English-language literature to date. Recently, however, we treated two patients with Pneumocystis carinii pneumoniawhodeveloped severe hyponatremia and hyperkalemia on administration of high-dose Tmp-Smx.These electrolyte disturbances were attributable to the direct effect of Tmp-Smxon the renal distal tubules, were reversible, and corrected by infusion of a sodium-enriched and potassium-free liquid. Therefore, it is suggested that even after electrolyte disturbances have occurred, high-dose Tmp-Smxtherapy may be continued for severe infectious diseases under appropriate electrolyte correction. (Internal Medicine 34: 96-99, 1995) 
Introduction
Trimethoprim-sulfamethoxazole (Tmp-Smx) is an antimicrobial agent which is effective for Pneumocystis carinii infection. This drug is excreted from the kidney and is known to have side effects such as acute tubular necrosis and interstitial nephritis (1) (2) (3) . Tmp-Smxhas been reported to cause renal salt wasting and metabolic acidosis (4), but appears to have no remarkableeffects on serum electrolyte levels as long as regular-dose Tmp-Smx is administered (5) . However, recent reports demonstrate that hyperkalemia occurred in patients with AIDSand Pneumocystis carinii pneumonia who were treated with high-dose Tmp-Smx (6) (7) (8) . In most of those cases, a causal relation between the Tmp-Smxtreatment and hyperkalemia is suggested but not proven because of the simultaneous presence of complications such as renal failure, adrenal insufficiency, and hypoaldosteronism (9) (10) (11) (12) . Recently, we experienced two cases with severe hypo-natremia and hyperkalemia associated with high-dose Tmp-Smxtherapy. In contrast to the patients with AIDSwho have been reported, our cases are free from complications which may cause electrolyte disturbances. Therefore, Tmp-Smxis suggested to act directly on the distal nephrons, causing a decrease in the renal sodium reabsorption and the renal potassium excretion.
Case Reports

Case1
A 64-year-old manwas admitted because of night sweat and fever. Physical examination revealed lymph node enlargement. A chest X-ray film showed bilateral hilar lymphadenopathy with no other abnormality in the bilateral lungs. The biochemical data were as follows: total protein 7.4 g/dl, albumin 3.5 g/ dl, sodium (Na) 139 mmol/1, potassium (K) 4.5 mmol/1, chloride (Cl) 102 mmol/1, blood urea nitrogen (BUN) 12.4 mg/dl, creatinine 1.0 mg/dl, uric acid 6.4 mg/dl, lactate dehydrogenase (LDH) 321 IU/1 (normal, 83-166 IU/1), alkaline phosphatase (ALP) 428 IU/1 (normal, 66-220 IU/1), and C-reactive protein (CRP) 7.3 mg/dl. White blood cell (WBC) count, hemoglobin (Hb), andplateletcount were 5Ax109/l, 1 1.2 g/dl, and 213x109/ 1, respectively. He was diagnosed as Hodgkin's disease (mixed cellularity) on lymph node biopsy. After 5 courses of VEPA regimen (vincristine 1 mg/day, endoxan 30 mg/day, prednisolone 40 mg/day, and adriamycin 40 mg/day), both clinical and laboratory findings improved (LDH 171 IU/1, ALP 196 IU/ 1, and CRP 0.3 mg/dl).
However, he developed fever and hypoxemia (PO2 65.6 mmHgon room air), and chest X-ray films and computed lungs. Pneumocystiscarinii pneumoniawas suspected and Tmp-Smx (12 g per day) was given. Thereafter, the serum levels of sodium and potassium began to change (Figs. 1, 2 ). Though oral intake plus intravenous infusion of sodium and potassium per day were around 300 mmoland 50 mmol respectively, the potassium concentration increased to 6.6 mmol/1after 3 days of administration and the serum sodium concentration decreased to 109 mmol/1 after 4 days. In association with the development of hyponatremia, his consciousness level decreased. He had no abnormality in ECG. Serum creatinine remained between 0.7 and 1.0 mg/dl, while BUNwas between 9.0 and 12.0 mg/dl. Creatinine clearance was 94 ml/ min and fractional excretion of sodium (FENa) was 2.6%.
These indicated that the electrolyte disturbances were not due to a reduced renal function. In addition, the decrease in serum sodium was associated with increased urinary sodium excretion, while the increase in serum potassium was associated with inhibited urinary potassium excretion (Figs. 1, 2). From this, it was supposed that the electrolyte abnormalities might be corrected by changing the amount of electrolytes in the infusion fluid. Therefore, from the 6th day of the Tmp-Smxtreatment, a fluid with high sodium (380 mmol per day) and no potassium was infused. The severe hyponatremia and hyperkalemia were corrected promptly and his consciousness was recovered. At this time, creatinine clearance was 90 ml/min and FENawas 3.5%. After 1 1 days of the Tmp-Smxtreatment, Tmp-Smxwas discontinued because the chest X-ray and CT findings of the pneumonia improved and pancytopenia developed (WBCcount 2.8xlO9/l, Hb 5.8 g/dl, and platelet count 76xlO9/l). Then, the sodium excretion into the urine decreased and the potassium excretion into the urine continued, and both serum sodiumand potassium levels returned to the normal range. The infusion was changed to the previous one, containing 150 mmolof sodium and 50 mmol of potassium per day (Figs. 1, 2) . The electrolyte disturbances disappeared and the pancytopenia induced by Tmp-Smxresolved. On the other hand, the Hodgkin's disease deteriorated 3 months later. He had high-grade fever and laboratory study revealed the following values: LDH307 IU/1, ALP 2,223 IU/1, and CRP 1 0.6 mg/dl. From these data, an infiltration ofHodgkin cells into the liver was suspected and he was treated with ABVD regimen (adriamycin 30 mg/day, bleomycin 10 mg/day, vinblastine 8 mg/day, and dacarbazine 500 mg/day). Regular-dose Tmp-Smx(2 g per day) was given prophylactically against expected Pneumocystis carinii pneumonia following druginduced agranulocytosis. During the course of this regular-dose Tmp-Smxtreatment, neither hyponatremia nor hyperkalemia has ever been recognized.
Case2
A 59-year-old man was admitted for chemotherapy of acute myeloblastic leukemia. He was afebrile, and WBCcount, Hb, and platelet count were 17.4xlO9/l, 6.9 g/dl, and 72xlO9/l, respectively. Differential count of WBCwas as follows: At 6 months after admission, his WBCcount, Hb, and platelet count were 71.9xlO9/l, 6.9 g/dl, and 1.6xlO9/l, respectively. Serum creatinine was 0.9 mg/dl and BUNremained between 12 and 26 mg/dl. These data indicated that renal function had improved. At that time, however, Pneumocystis carinii pneumonia was suspected on chest X-ray films, and Tmp-Smxwas given at a dose of 12 g a day. Biochemical data at the beginning of the Tmp-Smx treatment were: Na 141 mmol/1, K 2.7 mmol/1, Cl 105 mmol/1, BUN 14.9 mg/dl, creatinine 0.9 mg/dl, and FENa 0.3%. Blood gas analysis was as follows: pH 7.489, PCO2 35.9 mmHg, PO2 90.6 mmHg, and bicarbonate 27.3 mmol/1 on oxygen at 3 1/min. On the 6th day of the Tmp-Smx administration, Na, K, Cl, BUN, and creatinine were 126 mmol/1, 5.2 mmol/1, 104 mmol/1, 29.1 mg/dl, and 1. 1 mg/dl, respectively (Figs. 3, 4) . In association with this electrolyte disturbance, marked metabolic acidosis developed (pH 7.293, PCO2 27 mmHg, PO2 151 mmHg, and bicarbonate 13 mmol/1 on oxygen at 3 1/min), but his consciousness level was not altered. Urine study showedthat the sodium excretion into the urine increased and FENa increased from 0.3% to 3.3% in spite of the low serum sodium level, while the potassium excretion into the urine did not increase remarkably even with the elevated serum potassium level (Figs. 3, 4) . Creatinine clearance was between 50 and 65 ml/min. From these results, it is supposed that the electrolyte abnormalities might be corrected by changing the amount of electrolytes in the infusion fluid. Onthe 7th day, therefore, the sodium infusion was increased to 300 mmolper day and potassium-free fluid was used, which rapidly corrected the abnormal serum electrolyte levels (Figs. 3, 4) . On the 10th day, Tmp-Smxwas replaced by pentamidine since the pneumonia did not improve. Thereafter, concentrations of serum sodium and potassium, FENa, and creatinine clearance were settled within normal ranges. BUN and creatinine returned to the previous levels and the metabolic acidosis disappeared.
Discussion
Electrolyte disturbances are considered to be very rare adverse effects of Tmp-Smxwhen it is given at regular doses (6) (7) (8) . At high doses, however, Tmp-Smx is expected to induce hyponatremia and hyperkalemia, since this drug has been reported to cause renal salt wasting (4) . In the present two cases, high-dose Tmp-Smx (12 g per day) decreased serum sodium and increased serum potassium. In spite of the low serum sodium and high serum potassium levels, the sodium excretion into the urine increased while the potassium excretion into the urine did not increase significantly. These data suggest that potassium excretion in the renal distal tubules. Trimethoprim (Tmp) is a heterocyclic weak base structurally related to amiloride which is a potassium-sparing diuretic agent. Tmpacts the same way as amiloride: it blocks reabsorption of sodium in the distal tubules, decreasing the lumennegative transepithelial voltage. This secondarily decreases potassium secretion and induces hyperkalemia (5, 7, 8) . Recent animal experiments also suggest that Tmpreversibly inhibits renal potassium secretion in a dose-dependent manner (6) (7) (8) .
From these findings, it can be speculated that the electrolyte disturbances seen in our present two cases are due to a direct action of Tmp-Smx on the renal distal tubules. According to the recent reports on AIDSpatients with Pneumocystis carinii pneumonia, hyperkalemia is recognized in 44 to 70%of patients who are given Tmp-Smxat high doses (6) (7) (8) (13) (14) (15) (16) . This hyperkalemia is also supposed to be due to high-dose Tmp-Smx therapy which causes reduced sodium reabsorption and potassium excretion in the distal tubules. However, many of these patients had severe complications such as renal failure and adrenal insufficiency which have profound effects on serum electrolytes. Therefore, it was difficult to interpret the action of Tmp-Smx accurately. In contrast, our present two cases have no severe complications whichcould cause severe electrolyte disturbances. The adrenal functions of these patients appeared to be preserved, since no suggestive symptomsand signs of adrenal insufficiency were appreciated and CT findings of adrenal glands were normal. This provides further support for the speculation that Tmp-Smxat high doses acts directly on the renal distal tubules and thereby inhibits sodium reabsorption and potassium excretion. On the other hand, reuptake of sodium is supposed to be moderately inhibited by regular-dose Tmp-Smx(6-8). However, no significant changes were observed in serum sodium and potassium levels of those AIDS patients and our case one when treated with regular-dose Tmp-Smx.This suggests the possible existence of someunknown mechanisms whichcan compensatemild hyponatremia and hyperkalemia. In our present two cases, hyperkalemia and hyponatremia developed rapidly after the administration of high-dose TmpSmxand resolved spontaneously on its discontinuation. This points to a possibility that Tmp-Smxalters sodium reabsorption and potassium excretion without causing any irreversible organic damage to the distal tubules. Moreover, Tmp-Smxinduced electrolyte disturbances can be corrected by sodium infusion and potassium deprivation. Therefore, when abso- 
